2014

Jeffrey Stein, Ph.D. Joins Sofinnova Ventures as a Life Science Venture Partner in San Diego

    SAN FRANCISCO, June 2 /PRNewswire/ -- Sofinnova Ventures, a San Francisco
 venture firm investing in early-stage life science and information technology
 companies, announced today that Jeffrey Stein, Ph.D. has joined the firm as a
 life science venture partner and Kauffman Fellow.  Stein will work with
 Sofinnova's life science investment team to identify San Diego-based
 investment opportunities in the area of biopharmaceutical clinical
 development, and advise the firm's life science portfolio companies on
 clinical and business matters.
     Stein has held senior scientific and management positions in the
 biopharmaceutical industry for the past 12 years. Previously he was a founder,
 Director and Chief Scientific Officer of Quorex Pharmaceuticals, which was
 acquired by Pfizer in 2004. Prior to founding Quorex, Stein was Principal
 Scientist at Diversa Corporation. He was also a Principal Investigator at the
 Agouron Institute, where his group pioneered the cloning and expression of
 multi-gene small molecule pathways. Stein currently consults for UC San Diego
 in venture development and technology spin-outs and will continue in this
 role.
     "Sofinnova is a compelling opportunity for me because of the firm's strong
 track record in both the biotechnology and information technology industries,
 and because the partners are so highly regarded by their peers," said Stein.
 "In addition, as a Kauffman Fellow I felt that the compact, experienced team
 of investment professionals at Sofinnova would provide an ideal dynamic for me
 to make near-term contributions. I feel very fortunate to be associated with
 this team."
     "Jeff's excellent scientific and entrepreneurial backgrounds will posture
 him to provide real value to Sofinnova's life science portfolio companies,"
 commented Mike Powell, Ph.D., Managing Director at Sofinnova Ventures. "He'll
 be a strategic asset to Sofinnova as well, because he's well-positioned to
 identify some of the significant biopharmaceutical investment opportunities in
 San Diego, a region rich with scientific innovation."
     Stein received his Ph.D. from the University of California, San Diego as a
 NASA Fellow and conducted postdoctoral research as an Alexander Hollaender
 Distinguished Postdoctoral Fellow at Caltech. Among the various honors Stein
 has received is the Thomas Alva Edison Patent Award.  He currently serves on
 the board of Rx3 Pharmaceuticals.
 
     About Sofinnova Ventures
     Sofinnova Ventures is a venture capital firm emphasizing a diversified
 investment strategy through financing early stage companies in the life
 science and information technology sectors. Founded in 1974, the San
 Francisco-based firm currently has $600 million under management. Sofinnova's
 mission is to create value by providing entrepreneurs with the resources,
 experience and networks necessary to turn their bright ideas into thriving
 businesses. With deeply rooted ties to Europe's leading financial, technology
 and venture institutions, Sofinnova is also uniquely positioned to foster
 trans-Atlantic synergy and market acceleration. For more information, visit
 www.sofinnova.com.
 
 

SOURCE Sofinnova Ventures

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.